
Elubrixin tosylate
CAS No. 960495-43-6
Elubrixin tosylate( SB-656933 )
Catalog No. M16860 CAS No. 960495-43-6
Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 177 | In Stock |
![]() ![]() |
10MG | 292 | In Stock |
![]() ![]() |
25MG | 613 | In Stock |
![]() ![]() |
50MG | 896 | In Stock |
![]() ![]() |
100MG | 1449 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameElubrixin tosylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionElubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.
-
DescriptionElubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist; inhibits CXCL1-induced CD11b up-regulation on PMNs in an in vitro whole blood assay and to be active in in vivo rodent inhalation challenge models of airway inflammation that used endotoxin and ozone to induce airway neutrophilia.Fibrosis Phase 2 Discontinued.
-
In VitroElubrixin has an inhibitory effect on neutrophils in a dose-dependent fashion.
-
In Vivo——
-
SynonymsSB-656933
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research AreaOther Indications
-
IndicationFibrosis
Chemical Information
-
CAS Number960495-43-6
-
Formula Weight635.503
-
Molecular FormulaC24H25Cl2FN4O7S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (196.69 mM)
-
SMILESCC1=CC=C(C=C1)S(=O)(=O)O.C1CN(CCN1)S(=O)(=O)C2=C(C=CC(=C2O)NC(=O)NC3=C(C(=CC=C3)F)Cl)Cl
-
Chemical Name1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea tosylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lazaar AL, et al. Br J Clin Pharmacol. 2011 Aug;72(2):282-93.
2. Nicholson GC, et al. Pulm Pharmacol Ther. 2007;20(1):52-9.
3. Kaur M, et al. J Pharmacol Exp Ther. 2013 Oct;347(1):173-80.
4. Busch-Petersen J, et al. Curr Top Med Chem. 2006;6(13):1345-52.
molnova catalog



related products
-
AZD 2098
AZD2098 is a potent, selective, orally bioavailable CCR4 receptor antagonist with pIC50 of 7.8 for hCCR4, pIC50 of 8.0 for rCCR4.
-
JNJ-27141491
A potent, selective, noncompetitive, orally active CCR2 antagonist with IC50 of 172 nM.
-
INCB-3344
A potent, selective and orally bioavailable CCR2 antagonist with IC50 of 5.1 nM and 9.5 nM for hCCR2 and mCCR2, respectively.